Amocarzine is an antifilarial antihelminthic drug, derived from amoscanate, that is active against the adult worms of Onchocerca volvulus. In animal studies of filarial infections, amocarzine showed promise as a macrofilaricidal drug and was afterward extensively tried in humans. Amocrazine has an adverse effects: dizziness, itching and rush. There were reversible neurological symptoms, such as impaired coordination and a positive Romberg’s sign. In a study from Ghana, the combination of ivermectin and amocarzine was not more effective than ivermectine alone and adverse effects were more severe. Amocarzine has no role in the treatment of onchocerciasis in Africa. In silico data emphasize that amocarzine could be potential lead compound that can be further developed into nematicidal chemical against Bursaphelenchus xylophilus.